8-K: ALX Oncology Reports Q3 2025 Results, Advances Pipeline

ALX Oncology announced its third-quarter 2025 financial results and provided a corporate update, highlighting positive ASPEN-06 data and progress in its ALX2004 and ASPEN-09 trials.

Summary

• ALX Oncology reported a GAAP net loss of ($22.1) million, or ($0.41) per basic and diluted share, for the three months ended September 30, 2025, an improvement from ($30.7) million, or ($0.58) per share, in the prior-year period.
• Cash, cash equivalents, and investments totaled $66.5 million as of September 30, 2025, with a projected cash runway into Q1 2027.
• Pre-planned exploratory analysis of the ASPEN-06 trial in HER2+ gastric cancer showed that evorpacept combined with TRP (trastuzumab, ramucirumab, and paclitaxel) achieved a 65.0% objective response rate (ORR) in patients with high CD47 expression, compared to 26.1% for TRP alone.
• In CD47-high HER2+ gastric cancer patients, evorpacept + TRP demonstrated a median duration of response (DOR) of 25.5 months versus 8.4 months for TRP, a progression-free survival (PFS) of 18.4 months versus 7.0 months (HR 0.39), and an overall survival (OS) of 17 months versus 9.9 months (HR 0.63).
• The Phase 2 ASPEN-09-Breast Cancer trial, evaluating evorpacept in HER2+ breast cancer patients previously treated with ENHERTU, is on track for First Patient In (FPI) in Q4 2025, with interim data expected in Q3 2026.
• Enrollment for the Phase 1 trial of ALX2004, a novel EGFR-targeted antibody-drug conjugate (ADC), began in August 2025 and has cleared the first dose cohort (1 mg/kg) without dose-limiting toxicities, now enrolling the second dose cohort (2 mg/kg); initial safety data is anticipated in 1H 2026.
• Detailed results from the Phase 2 ASPEN-03 and ASPEN-04 trials for recurrent, unresectable or metastatic head and neck squamous cell carcinoma (HNSCC) confirmed that they did not meet their primary endpoints, leading the company to discontinue evorpacept in combination with PD-1 inhibitors for this indication.
• Barbara Klencke, M.D., a current Board Member, has been appointed as interim Chief Medical Officer.

Sentiment

Score: 7

Explanation: The positive clinical data for evorpacept in a targeted patient population and the promising early progress of ALX2004 are strong positives. The extended cash runway also provides stability. However, the failure of ASPEN-03/04 trials and ongoing net losses temper the overall sentiment, indicating continued high-risk, high-reward profile typical of a clinical-stage biotech.

Positives

• Evorpacept demonstrated compelling and durable clinical benefit in CD47-high HER2+ gastric cancer patients in the ASPEN-06 trial, with a 65.0% ORR, 25.5 months median DOR, 18.4 months PFS (HR 0.39), and 17 months OS (HR 0.63).
• Identification of CD47 overexpression as a key predictive biomarker for evorpacept efficacy supports a targeted clinical development strategy.
• The ALX2004 Phase 1 trial is progressing well, having cleared the first dose cohort (1mg/kg) without dose-limiting toxicities and now enrolling the second (2mg/kg).
• ALX2004 showed potent preclinical anti-tumor activity across multiple tumor types and a favorable preclinical safety profile, including no skin toxicity or interstitial lung disease.
• The company's cash, cash equivalents, and investments of $66.5 million are expected to fund planned operations into Q1 2027, providing financial stability.
• GAAP net loss decreased to ($22.1) million in Q3 2025 from ($30.7) million in Q3 2024, primarily due to lower R&D expenses.
• The appointment of Dr. Barbara Klencke as interim Chief Medical Officer brings over 30 years of experience in oncology drug development to the leadership team.

Negatives

• The ASPEN-03 and ASPEN-04 clinical trials for HNSCC did not meet their primary endpoints, leading to the discontinuation of evorpacept in combination with PD-1 inhibitors for this indication.
• The company continues to report a net loss, with a GAAP net loss of ($22.1) million for Q3 2025 and ($78.8) million for the nine months ended September 30, 2025.
• Cash, cash equivalents and investments decreased from $131.3 million at December 31, 2024, to $66.5 million at September 30, 2025.

Risks

• Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied.
• Clinical trials, such as ASPEN-09 and ALX2004, may not achieve their primary endpoints, demonstrate efficacy, or maintain a favorable safety profile.
• The company's decision to discontinue evorpacept in combination with PD-1 inhibitors for HNSCC indicates the inherent challenges and potential failures in drug development programs.
• The hypothesis that CD47 expression is a key predictive biomarker for evorpacept efficacy needs further validation in other clinical settings.

Future Outlook

ALX Oncology expects its cash runway to extend into Q1 2027, supporting key milestones including initial safety data for ALX2004 in 1H 2026 and interim data for ASPEN-09-Breast Cancer in Q3 2026. The company is prioritizing evorpacept development in combination with anti-cancer antibodies that directly induce ADCP, based on positive ASPEN-06 data, and will not pursue evorpacept in combination with PD-1 inhibitors at this time.

Management Comments

• "We are pleased to share data at SITC this weekend from an analysis of our ASPEN-06 trial demonstrating compelling benefit in all outcomes measured for patients with high CD47-expressing HER2-positive gastric cancer treated with evorpacept in combination with trastuzumab, ramucirumab, and paclitaxel." Jason Lettmann, Chief Executive Officer.
• "This insight is guiding our targeted clinical development strategy for breast cancer where we will be enrolling patients with HER2-positive tumors that have previously received ENHERTU and we will evaluate responses by CD47-expression level in our Phase 2 ASPEN-09-Breast Cancer trial." Jason Lettmann, Chief Executive Officer.
• "Additionally, we are excited about the progress of our ALX2004 clinical program, where we are currently enrolling the second dose cohort at 2mg/kg after clearing the dose 1 cohort at 1mg/kg, a milestone for this Phase 1 program." Jason Lettmann, Chief Executive Officer.
• "We look forward to providing an update with initial safety data from this program in the first half of next year." Jason Lettmann, Chief Executive Officer.
• "Given the promising preclinical findings we have seen to date for ALX2004 which demonstrate a favorable toxicity profile and potent anti-tumor activity, we remain very optimistic about the potential success for this approach in treating EGFR+ tumors." Jason Lettmann, Chief Executive Officer.

Industry Context

The oncology sector continues to focus on targeted therapies and combination approaches. ALX Oncology's strategy to leverage CD47 expression as a predictive biomarker for evorpacept aligns with the industry trend towards personalized medicine. The development of ALX2004, an EGFR-targeted ADC, also reflects the growing interest in ADCs as a promising class of cancer therapeutics, especially given its favorable preclinical safety profile without common ADC toxicities like skin toxicity or interstitial lung disease. The shift away from PD-1 inhibitor combinations for evorpacept in HNSCC highlights the challenges of immuno-oncology combinations and the need for precise mechanistic understanding.

Comparison to Industry Standards

• The ASPEN-06 data showing a 65.0% ORR for evorpacept + TRP in CD47-high HER2+ gastric cancer patients significantly outperforms the 26.1% ORR for TRP alone, suggesting a substantial improvement over standard of care in this specific patient population.
• The median DOR of 25.5 months for evorpacept + TRP compared to 8.4 months for TRP alone in CD47-high HER2+ gastric cancer is a notable extension, indicating durable clinical benefit.
• The PFS of 18.4 months vs. 7.0 months (HR 0.39) and OS of 17 months vs. 9.9 months (HR 0.63) in CD47-high HER2+ gastric cancer patients are strong indicators of efficacy, potentially positioning evorpacept as a significant advancement for this difficult-to-treat population.
• The company's focus on ADCP-inducing antibodies for evorpacept, following the ASPEN-03/04 setbacks with PD-1 inhibitors, reflects a strategic pivot common in drug development when initial combination hypotheses do not pan out.
• ALX2004's preclinical profile, specifically the absence of skin toxicity or interstitial lung disease in NHP toxicology studies, differentiates it from some other EGFR-targeted ADCs or ADCs in general, which can face such challenges.

Management Changes

Stakeholder Impact

• Shareholders: Positive clinical data and pipeline progress could increase investor confidence, while ongoing losses and trial failures present risks. Extended cash runway provides reassurance.
• Patients: Potential for new, effective treatments for HER2+ gastric cancer and HER2+ breast cancer, and EGFR-expressing solid tumors.
• Employees: Strategic prioritization and pipeline advancements could provide clarity and focus.

Next Steps

• Present ASPEN-06 data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting on November 8th.
• Begin enrollment (First Patient In) for the Phase 2 ASPEN-09-Breast Cancer trial in Q4 2025.
• Deliver initial safety data for the ALX2004 Phase 1 trial in 1H 2026.
• Anticipate interim data readout for the ASPEN-09-Breast Cancer trial in Q3 2026.
• Continue enrolling patients in the second dose cohort (2mg/kg) for the ALX2004 Phase 1 trial.

Key Dates

Recommendation

The positive ASPEN-06 data for evorpacept in a specific, high-need patient population (CD47-high HER2+ gastric cancer) and the promising early safety and preclinical profile of ALX2004 are significant catalysts. The extended cash runway into Q1 2027 provides a solid financial footing to reach key milestones. However, the failure of the ASPEN-03 and ASPEN-04 trials for HNSCC highlights the inherent risks in drug development and the need for further validation of evorpacept's mechanism in other indications. While there are clear positives, the company remains a clinical-stage biotech with ongoing losses and significant future development hurdles. A "hold" recommendation reflects the balance between the promising clinical advancements and the continued high-risk profile, suggesting investors monitor upcoming data readouts closely.

Keywords

ALX Oncology, ALXO, evorpacept, ALX2004, CD47, HER2+ gastric cancer, breast cancer, EGFR-targeted ADC, oncology, biotechnology, clinical trials, financial results, Q3 2025, ASPEN-06, ASPEN-09, SITC, ESMO, AACR-NCI-EORTC